We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Still in reach

25 June 2007 By Robert Cyran

The US pharma group would be a tasty morsel for one of its bigger competitors. Its market cap has risen by a third on bid speculation. But it s still within reach of the industry s usual suspects when you factor in typical cost savings in pharma mergers.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)